All Content Outsourced Pharma

81. FUJIFILM Diosynth Biotechnologies Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Director of Commercial Development, Serat Ali, describes FDBs' Advanced Therapy capabilities, discusses their global facilities network, and provides a capacity update.

82. PCI Pharma Services To Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea 4/24/2025

    PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative biopharma therapies – is acquiring an entire equity stake in Ajinomoto Althea, Inc. (“Althea”), a US-based sterile fill-finish CDMO and 100% subsidiary of Japan-based Ajinomoto Co., Inc. Scheduled for completion in May 2025, the acquisition provides PCI with its first-ever North American manufacturing location for prefilled syringes and cartridges – including isolator technology for these formats – as well as high potent manufacturing suitable for antibody-drug conjugates (ADCs).

83. PDG-FDA Town Hall Notes — DSCSA Readiness Is At Hand 4/24/2025

    Data quality and exceptions handling were key discussion points during a March PDG-FDA town hall, where stakeholders shared updates on progress and unfinished work.

84. Big Pharma Insights For Building Biotech Startups With Uniquity Bio's Brian Lortie 4/24/2025

    On this episode of the Business of Biotech, host Ben Comer speaks with Brian Lortie, President and CEO of Uniquity Bio, about his "no jerk" policy and how his experience building teams at GSK, Endo Pharmaceuticals, and Onspira Therapeutics informs his leadership at Uniquity, a clinical-stage immunology startup backed by Blackstone Life Sciences.

85. The Strategic Role Of Cost Modeling In Pharmaceutical Procurement 4/24/2025

    Selecting a CDMO depends on price, geography, expertise, and other variables. While price is often a key motivation for the decision, it is production cost that should be carefully considered. An independent analysis can be of great help. An Outsourced Pharma Board member presents some scenarios.

86. Vinta Bio Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Uncover how an intensified adherent AAV manufacturing process is unlocking high-yield, low-impurity clinical production with over 95% full capsids in a streamlined, compact platform.

87. Kincell Bio Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Explore how expert CMC strategies and clinical manufacturing experience can lay the groundwork for the successful commercialization of advanced cell therapies.

88. Comprehensive Cell Solutions Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Discover how NYBCe and CCS are transforming cell and gene therapy development with end-to-end CDMO solutions, advanced logistics, and a growing innovation hub in Louisville.

89. Miltenyi Biotec B.V. & Co. KG Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    In this presentation, Shaan Gareeb highlights the capabilities of our Cell Therapy Center of Excellence in San Jose, California, one of five global Miltenyi Bioindustry sites.

90. Andelyn Capacity Update April 2025: Cell & Gene Therapy 4/24/2025

    Focusing on critical parameters such as cell culture conditions, viral vector yield, and downstream purification strategies, can drive the success of scale-up and scale-down models for AAV production.